Bluejay Diagnostics

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Bluejay Diagnostics sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 2 currently recruiting 1 completed upper quartile by trial count

Bluejay Diagnostics: 3 sponsored US clinical trials, 2 recruiting.

Bluejay Diagnostics sponsors 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. The most-studied condition in this pipeline is Sepsis, Septic Shock, with 1 trials.

Upper-quartile sponsor footprint

Bluejay Diagnostics sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Bluejay Diagnostics pipeline

2 recruiting of 3 indexed (67% open); 1 completed (33%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Sepsis, Septic Shock (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Bluejay Diagnostics: open-pipeline peers nationwide

Peers matched on 3 registered trials and 67% open enrollment, not the therapeutic-area sidebar.

Bluejay Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 234567 0%20%40%60%80% Total trials Recruiting share Bluejay Diagnostics10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAbbisko Therapeutics CoABL BioAccelerated Cure Project for Multiple SclerosisAdvanced Reconstructive Surgery Alliance
Bluejay Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Bluejay Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 67% open enrollment (± trial volume)

What to do with this Bluejay Diagnostics page

3 registered trials is a research-attention snapshot, not an endorsement of Bluejay Diagnostics or any single study.

  • 2 of Bluejay Diagnostics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Sepsis, Septic Shock is the condition Bluejay Diagnostics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sepsis, Septic Shock trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Bluejay Diagnostics pipeline card: 3 registered trials from official public datasets.Report a data error.